News & Publications

Mike Kope talks with Phil Newman of Longevity.Technology about Cyclarity

Watch Cyclarity CEO of Corporate Affairs Mike Kope talk with Phil Newman of Longevity.Technology about tackling oxidized cholesterol and taking on the world’s biggest killer.

You can read more HERE at Longevity.Technology.

 

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Mike Kope presents at the Rejuvenation Startup Summit 2022

Watch Cyclarity’s CEO of Corporate Affairs Mike Kope discuss company strategy and the work to prevent age-related conditions such as atherosclerosis, heart attack, and stroke by addressing the root cause at the Rejuvenation Startup Summit 2022.

Thanks to Forever Healthy FoundationKIZOO Technology Capital, Frank Schueler & Michael Greve for an amazing inaugural event.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity Therapeutics has Moved to the Buck Institute for Research on Aging

Press Release

Novato, CA, U.S., June 24, 2022 – Announcing our move to the Buck Institute for Research on Aging.

Cyclarity Therapeutics (https://cyclaritytx.com) has just completed the move of its research and operations to the state-of-the-art labs at the Buck Institute for Research on Aging. We presented the progress of our lead program to the President and Senior Officers of the Buck Institute earlier this year, and they kindly extended an offer of tenancy. 

Our relationship with the Buck Institute offers not only access to a variety of important core facilities; we expect it offers a wonderful opportunity to expand our collaborations and relationships with many world leaders in cardiovascular disease, and the field of aging as a whole.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics

Press Release

Novato, CA, U.S., June 24, 2022 – Announcing our corporate name change and new branding.

We’re excited to announce that Underdog Pharmaceuticals has changed its name to Cyclarity Therapeutics.

We remain exactly on track to commence human clinical trials for UDP-003 in 2023. Now at the halfway point of 2022, the closer we get to this critical goal, the more exciting things have become here. Unfortunately, it has raised one significant problem for us:

In the race to cure atherosclerosis, it’s getting hard to refer to ourselves as the “Underdog!”

So we met with the Board, talked to select stakeholders and PR professionals (and a lawyer or two), and asked our shareholders to approve a new corporate name, the brand under which our team will strive to cure heart disease and to make our mark in the field of aging. We strove to connote vision, and to reference the clearance of toxic oxysterols and other by-products of aging that will remain our focus. So, welcome, all, to Cyclarity.

We have been fortunate to have the unwavering support of Kizoo Technology Ventures as our lead investor, and all of your support as our shareholders, collaborators and friends. Your clarity of vision helped get us this far, and we look forward now, with Cyclarity, to the commencement of human trials for what may be one of the most important rejuvenation drugs in development. Thank you.

About Cyclarity

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting oxidized cholesterol using rationally designed molecules, to provide the first true disease-modifying treatments for common age-related conditions such as atherosclerosis, heart attack and stroke. Its products are based on novel derivatives of a well-known, safe compound and a new way of looking at cardiovascular disease. For more information, please visit www.underdogpharma.com or send an email to press@cyclaritytx.com

Forward Looking Statements

The information and statements contained herein contain forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from such forward-looking statements and should not be considered as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company’s prospects or actual results to differ materially from those in the forward-looking statements. The Company does not undertake any obligation to update the information or forward-looking statements contained herein whether as a result of new information or future events or otherwise.

Contact:

Mike Kope
CEO of Corporate Affairs​
Cyclarity Therapeutics, Inc.
press@cyclaritytx.com

Cyclarity Therapeutics logos for media use:

KIZOO Technology Capital owner Michael Greve discusses recent scientific advancements with Drug Discovery World

KIZOO Technology Capital owner Michael Greve discusses the recent scientific advancements in addressing the root causes of age-related diseases in the rejuvenation biotechnology sphere—including the work of Underdog Pharmaceuticals. As one of Kizoo’s key startups, Underdog’s goal is to deliver affordable therapeutics for the prevention of heart disease and stroke through the removal of arterial plaque.

Media Contact for Kizoo:

Frank Schueler
Managing Director
Kizoo Technology Capital
fs@kizoo.com

Media Contact for Underdog:

Mike Kope
Co-CEO
Underdog Pharmaceuticals Inc
press@cyclaritytx.com

For media inquiries:

For general inquiries:

Cyclarity Therapeutics logos for media use: